Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice

BACKGROUND/AIMS: An interim analysis of post-marketing surveillance of CT-P13, an infliximab biosimilar, was performed to evaluate its safety and efficacy in Japanese patients with inflammatory bowel disease. METHODS: Patients were prospectively enrolled between November 2014 and March 2017, after t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakagawa, Tomoo, Kobayashi, Taku, Nishikawa, Kiyohiro, Yamada, Fumika, Asai, Satoshi, Sameshima, Yukinori, Suzuki, Yasuo, Watanabe, Mamoru, Hibi, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821950/
https://www.ncbi.nlm.nih.gov/pubmed/31422647
http://dx.doi.org/10.5217/ir.2019.00030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821950/
https://www.ncbi.nlm.nih.gov/pubmed/31422647
http://dx.doi.org/10.5217/ir.2019.00030

Ejemplares similares